Physician profile
Beshoy T Yanny
NPI 1417221243
$50,291.30
in general payments reported to CMS, 2019-2025
10 companies · $35K in 2025
The $35K reported for 2025 was more than what 88% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $278 · 2021: $94.53 · 2022: $416 · 2024: $14K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $3,218 · Travel and Lodging: $2,995 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,820.50 |
| Food and Beverage | $3,218.03 |
| Travel and Lodging | $2,994.91 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $40,606.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $7,171.12 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $1,072.53 | 2019-2025 | |
| Eton Pharmaceuticals, INC. | $1,000.00 | 2025 | Carglumic Acid, Galzin, Nitisinone |
| Intercept Pharmaceuticals, INC. | $178.17 | 2019 | |
| Novo Nordisk INC | $74.24 | 2025 | Wegovy |
| Echosens North America, INC. | $70.14 | 2019 | |
| Abbvie INC. | $58.91 | 2024 | |
| Vbi Vaccine (Delaware) INC. | $36.21 | 2022 | |
| Lilly USA, LLC | $23.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beshoy Yanny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.